APOTEX CORP. for APOTEX CORP.
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
S. 1315/HR 3777 the Drug Price Competition Act of 2009, all provisions S. 369 Preserve Access to Affordable Pharmaceuticals Act, all provisions Draft legislation concerning pharmaceutical manufacturing facility inspections, provision concerning registration fees for manufacturing facilities FDA Docket No. FDA-2010-N-0381 concerning generic drug user fees Propective action on legislation concerning the establishment of a generic drug user fee program Amending section 505(j)(5)(C)(ii)(I) of the Food, Drug and Cosmetic Act, concerning the ability of generic drug manufacturers to file counterclaims seeking the correction of incorrect information submitted to FDA's Orange Book by patent owners or holders of approved New Drug Applications.
Foreign entity interest: ApoSherm Inc., the parent company of Apotex Corp., has direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs, and therefore has an interest in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.